We are developing a portfolio of investigational psychedelic-based treatments with the aim of improving patient outcomes and easing the burden that mental health conditions have on individuals, healthcare systems and society.
Our investigational compounds have been designed to be administered in a short clinic visit, be well-tolerated and deliver rapid, robust and lasting treatment effects.
Our synthetic, proprietary, intranasal formulation of 5-MeO-DMT benzoate. It is currently under investigation in Phase II studies as a potential medication for depression and alcohol use disorder.
Our synthetic, proprietary, intravenous formulation of psilocin benzoate. It is currently under investigation in Phase II studies as a potential medication for depression.
We also have several new chemical entities (NCEs) in preclinical development.
Our novel synthetic intranasal formulation of 5-MeO-DMT benzoate
Treatment with BPL-003 comprises administration of BPL-003 in a clinical setting, with pre-dose preparation, in-dose safety monitoring and post-dose follow-up provided by healthcare professionals to support patients and ensure the safe use of the compound.Â
The BPL-003 treatment has been designed to overcome some of the challenges of first-generation psychedelics and existing mental health treatments and produce rapid, robust and lasting treatment effects with a short time in clinic of approximately 2 hours.Â
Rapid, robust and lasting response from a single dose
Findings from an open-label Phase IIa study investigating 10mg of BPL-003 in patients with Treatment Resistant Depression (depression that failed to respond to two or more prior treatments) who were not taking concomitant antidepressants found that:
A single administration of BPL-003 demonstrated a rapid antidepressant effect, with 55% of patients having a 50% or greater improvement in depression symptoms the day after dosing (day 2).
A robust and lasting antidepressant effect was shown, with 55% of patients meeting the criteria for remission from symptoms of depression at day 29 and 45% in remission at day 85.Â
BPL-003 required a short time in clinic, with patients deemed dischargeable within an average time of less than 2 hours. This underlies the potential to deliver a scalable treatment model that, if approved, could fit within the existing interventional psychiatry treatment paradigm.
Our novel synthetic intravenous formulation of psilocin benzoate
Treatment with ELE-101 comprises administration of ELE-101 in a clinical setting, with pre-dose preparation, in-dose safety monitoring and post-dose follow-up provided by healthcare professionals to support patients and ensure the safe use of the compound.Â
The ELE-101 treatment has been designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately 2 hours.
Links to other websites do not imply affiliation or endorsement. ¹û¶³ÊÓƵ does not control and is not responsible for their content.
